Abstract: A preparation method of sodium hyaluronate with a full molecular weight distribution (MWD) is provided, including: step 1): spraying hydrogen peroxide on a sodium hyaluronate solid raw material, and conducting an ultraviolet (UV) irradiation treatment; step 2): dissolving a sodium hyaluronate degradation material in water, and adjusting a pH to higher than 7.0; step 3): subjecting a sodium hyaluronate alkaline solution to an ultrasonic treatment; step 4): preparing the sodium hyaluronate solid raw material into a sodium hyaluronate solution with a concentration of 0.1% to 1% (w/v), and thoroughly mixing the sodium hyaluronate solution in an addition proportion of 20% to 60% (v/v) with the sodium hyaluronate alkaline solution obtained after the ultrasonic treatment; and step 5): subjecting a resulting mixed solution to an adsorption treatment with diatomaceous earth and activated carbon, filtering for concentration, and drying a resulting concentrate to obtain the sodium hyaluronate with a full MWD.

Abstract: A preparation method of sodium hyaluronate with a full molecular weight distribution (MWD) is provided, including: step 1): spraying hydrogen peroxide on a sodium hyaluronate solid raw material, and conducting an ultraviolet (UV) irradiation treatment; step 2): dissolving a sodium hyaluronate degradation material in water, and adjusting a pH to higher than 7.0; step 3): subjecting a sodium hyaluronate alkaline solution to an ultrasonic treatment; step 4): preparing the sodium hyaluronate solid raw material into a sodium hyaluronate solution with a concentration of 0.1% to 1% (w/v), and thoroughly mixing the sodium hyaluronate solution in an addition proportion of 20% to 60% (v/v) with the sodium hyaluronate alkaline solution obtained after the ultrasonic treatment; and step 5): subjecting a resulting mixed solution to an adsorption treatment with diatomaceous earth and activated carbon, filtering for concentration, and drying a resulting concentrate to obtain the sodium hyaluronate with a full MWD.

Abstract: A joint cavity injection preparation is provided. The active ingredient of the joint cavity injection preparation is deacetylated xanthan gum (XG). The deacetylated XG has a molecular weight of 500,000 to 20,000,000. The joint cavity injection preparation is prepared from deacetylated xanthan gum (XG), which has higher biocompatibility and safe wide-dosage range than existing joint cavity injection preparations prepared from XG.

Abstract: A joint cavity injection preparation is provided. The active ingredient of the joint cavity injection preparation is deacetylated xanthan gum (XG). The deacetylated XG has a molecular weight of 500,000 to 20,000,000. The joint cavity injection preparation is prepared from deacetylated xanthan gum (XG), which has higher biocompatibility and safe wide-dosage range than existing joint cavity injection preparations prepared from XG.

Abstract: The present invention relates to a method for preparation of heparin silver, to use of heparin silver in manufacture of medicine for treating burns and/or scalds, to a method of using heparin silver to treat burns and/or scalds, and to a topical preparation containing heparin silver for treating burns and/or scalds. The heparin silver product prepared according to the method of the present invention has a high purity and less impurity. The animal test proved that the medicine made by using heparin silver exhibited effects of accelerating wound healing and reducing scar formation.

Abstract: A pharmaceutical composition containing sunflower extract comprises the extract of total flavonoids from leaves, heads or stems of sunflower (Helianthus annuus L.), in which the content of total flavonoids is 50-90%. Preferably, the pharmaceutical composition comprises the extract of total terpenes and/or the extract of total organic acids. The pharmaceutical composition is used as an active ingredient in manufacture of foods, functional foods or medicaments for preventing or treating hypertension.

Abstract: The present invention discloses a bismuth hyaluronate, characterized in that the bismuth content is from 0.5% to 40%, and the glucuronate content is from 20% to 45%, based on dry weight. Also provided is a method for the preparation of said bismuth hyaluronate comprising reaction of a soluble hyaluronate salt with a bismuth salt in a basic aqueous solution, followed by steps of precipitation, filtration, desalting, dehydrating and drying to obtain the product. Further disclosed is the use of the bismuth hyaluronate in the manufacture of a medicament or health foods for preventing and treating gastrointestinal disorders, in particular ulcerous disorders of the GI tract. It has been proven in animal experiments to show a better therapeutic effect than products of the same type.

Abstract: The present invention relates to an oral formulation comprising a hyaluronic acid-phospholipid complex, and to use of a hyaluronic acid-phospholipid complex for the manufacture of a joint function-improving and protecting agent for oral administration which can alleviate the arthritic symptoms in patients with arthritic conditions, increase the concentration of hyaluronic acid in synovial fluid, improve the lubrication of joints, as well as maintain and enhance the normal functions of joints.

Abstract: The present invention discloses a bismuth hyaluronate, characterized in that the bismuth content is from 0.5% to 40%, and the glucuronate content is from 20% to 45%, based on dry weight. Also provided is a method for the preparation of said bismuth hyaluronate comprising reaction of a soluble hyaluronate salt with a bismuth salt in a basic aqueous solution, followed by steps of precipitation, filtration, desalting, dehydrating and drying to obtain the product. Further disclosed is the use of the bismuth hyaluronate in the manufacture of a medicament or health foods for preventing and treating gastrointestinal disorders, in particular ulcerous disorders of the GI tract. It has been proven in animal experiments to show a better therapeutic effect than products of the same type.

Abstract: The present invention relates to a method for preparation of heparin silver, to use of heparin silver in manufacture of medicine for treating burns and/or scalds, to a method of using heparin silver to treat burns and/or scalds, and to a topic topical preparation containing heparin silver for treating burns and/or scalds. The heparin silver product prepared according to the method of the present invention has a high purity and less impurity. The animal test proved that the medicine made by using heparin silver exhibited effects of accelerating wound healing and reducing scar formation.